Indirect comparison of efficacy of dupilumab *versus* mepolizumab and omalizumab for severe type 2 asthma

Copyright ©The authors 2021

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 6 May 2021
Accepted: 3 June 2021

To the Editor:

Recently, several biologics have been introduced as add-on treatment for severe asthma [1]. The biologics target the underlying mechanism driving the disease and are recommended for specific phenotypes such as mepolizumab (anti-interleukin (IL)-5) for severe eosinophilic asthma [2] and omalizumab (anti-immunoglobulin (Ig)E) for severe allergic asthma [3]; *i.e.* specific endotypes of type 2 inflammation. Dupilumab (anti-IL-4R α) is a newer biologic recommended for severe asthma with type 2 inflammation characterised by elevated blood eosinophils (≥ 150 per μL) and/or exhaled nitric oxide fraction ($F_{\text{eNO}} \geq 25$ ppb) [4]. Due to the IL-4R α activity of dupilumab it is likely to inhibit two type 2 inflammatory pathways and, therefore, a patient can be eligible for more than one of the biologics, which is challenging in practice as no previous study has compared the efficacy of dupilumab with mepolizumab and omalizumab.

The aim of this study was to compare the efficacy of dupilumab with mepolizumab and omalizumab in patients aged >12 years with severe type 2 asthma. Therefore, a predefined protocol was developed by an expert committee under the Danish Medicines Council, where two PICO questions were defined: “What is the safety and efficacy of dupilumab compared to mepolizumab?” and “What is the efficacy and safety of dupilumab compared to omalizumab?”

Outcomes were predefined as critical (exacerbations leading to a course of oral corticosteroids (OCS), emergency department visit or hospital admission, or reduction in maintenance OCS treatment) or important and a minimal clinically important difference (MCID) was predefined for each outcome. Dupilumab was compared with mepolizumab and omalizumab for eight outcomes: 1) reduction of annual exacerbations; 2) patients not experiencing exacerbations; 3) lung function measured by forced expiratory volume in 1 s (FEV_1); 4) patients achieving an improvement in $\text{FEV}_1 \geq 200$ mL; 5) asthma control measured with an Asthma Control Questionnaire; 6) quality of life measured with an Asthma Quality of Life Questionnaire; 7) incidence of serious adverse events (SAEs); and 8) specific subtypes of SAEs. Furthermore, dupilumab was compared with mepolizumab for three additional outcomes: OCS dosage reduction; patients able to eliminate OCS treatment; and patients with a reduction in OCS dosage of $\geq 50\%$.

A systematic literature review finalised during September 2019 identified 436 publications of which 33 based on 23 clinical studies were included. Three studies compared dupilumab with placebo [5–9], four compared mepolizumab with placebo, and 16 compared omalizumab with placebo or an active comparator. The initial literature search and analyses were done by Sanofi (Copenhagen, Denmark) and subsequently validated by the expert committee and the secretariat of the Danish Medicines Council.

Indirect comparisons were performed according to Bucher’s method. In the comparison of dupilumab with mepolizumab for severe eosinophilic asthma, we included dupilumab studies with a prespecified subgroup analysis on patients with blood eosinophils ≥ 150 per μL . This was possible in DRI12544 [6, 9] and QUEST [5, 7], but not in the VENTURE study [8]. Three comparisons were made to investigate the effect on outcomes: A: severe eosinophilic asthma, 24–32 weeks treatment; B: severe eosinophilic asthma, 52 weeks treatment; and C: OCS dependent severe eosinophilic asthma, 24 weeks treatment.

Shareable abstract (@ERSpublications)

This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differences <https://bit.ly/3pK9Nf9>

Cite this article as: Prætorius K, Henriksen DP, Schmid JM, *et al.* Indirect comparison of efficacy of dupilumab *versus* mepolizumab and omalizumab for severe type 2 asthma. *ERJ Open Res* 2021; 7: 00306-2021 [DOI: 10.1183/23120541.00306-2021].

TABLE 1 Results of indirect comparisons using Bucher's test for dupilumab *versus* mepolizumab and dupilumab *versus* omalizumab for treatment of severe type 2 asthma

Outcome	Unit of measurement	MCID	Dupilumab [#] <i>versus</i> mepolizumab [¶]		Dupilumab <i>versus</i> omalizumab ⁺	
			Difference in absolute values (95% CI)	Difference in relative value (95% CI)	Difference in absolute values (95% CI)	Difference in relative value (95% CI)
Exacerbation rate	Mean reduction of annual exacerbations, n	0.5 exacerbation per year	B: -0.19 (-0.53–0.32), p=0.39	B: 0.85 (0.57–1.26), p=0.43	B: -0.11 (-0.27–0.11), p=0.26	B: 0.85 (0.61–1.17), p=0.33
	Percentage of patients without exacerbations	10%	B: -10.6 (-21.9–4.5), p=0.12	B: 0.80 (0.60–1.08), p=0.14	B: 2.6 (-5.6; 12.2), p=0.58	B: 1.05 (0.90–1.21), p=0.53
OCS maintenance treatment	Mean % reduction of daily OCS dose	20% (at least 2.5 mg prednisolone equivalent)				
	Percentage of patients able to eliminate daily OCS treatment	5%	C: -0.5 (-9.9–27.6), p=0.94	C: 0.97 (0.31–2.91), p=0.96		
	Percentage of patients with a reduction of OCS daily dose $\geq$ 50%	10%	C: -1.4 (-21.0–29.9), p=0.92	C: 0.97 (0.61–1.57), p=0.91		
Lung function, FEV ₁	Mean difference in FEV ₁	200 mL	A: +100 (13–188), p=0.025 B: +189 (62–316), p=0.004 C: +106 (-122–334), p=0.37		B: +96 (11–182), p=0.028	
	Percentage of patients who achieved an improvement in FEV ₁ $\geq$ 200 mL	15%				
ACQ	Mean difference in ACQ	0.5	A: -0.02 (-0.22–0.18), p=0.86 C: 0.05 (-0.41–0.51), p=0.84		A: -0.11 (-0.42–0.20), p=0.50	
AQLQ	Mean difference in AQLQ	0.5	A: -0.13 (-0.32–0.06), p=0.18 C: -0.01 (-0.41–0.40), p=0.96		A: -0.08 (-0.30–0.15), p=0.50	
SAEs	Total incidence of SAEs	5%	A: 6.5 (-1.6–27.5), p=0.39 B: 2.0 (-5.7–17.6), p=0.75 C: 26.0 (1.5–257.1), p=0.013	A: 1.97 (0.76–5.13), p=0.16 B: 1.15 (0.57–2.35), p=0.71 C: 19.55 (2.10–184.6), p=0.009	A: 3.0 (-1.8–14.9), p=0.49 B: 0.2 (-2.7–5.3), p=0.93	A: 1.61 (0.64–4.05), p=0.32 B: 1.04 (0.60–1.80), p=0.90
	Specific subtypes of SAEs, e.g. anaphylaxis		No analysis	No analysis		

All estimates are for dupilumab compared to mepolizumab and omalizumab. MCID: minimal clinically important difference; OCS: oral corticosteroids; FEV₁: forced expiratory volume in 1 s; ACQ: Asthma Control Questionnaire; AQLQ: Asthma quality of life Questionnaire; SAE: serious adverse events. A: severe asthma, 24–32 weeks treatment; B: severe asthma, 48–52 weeks treatment; C: OCS-dependent asthma, 24 weeks treatment. [#]: dupilumab studies: [10–14]; [¶]: mepolizumab studies: [15–18]; ⁺: omalizumab studies: [19–40].

In the comparison of dupilumab with omalizumab for severe allergic asthma, we included dupilumab studies with subgroup analysis defined by total IgE ≥ 30 IU·mL⁻¹, perennial inhalant allergy, and one of the following: blood eosinophils ≥ 150 per μ L or $F_{eNO} \geq 25$ ppb. Two comparisons were made as there were no omalizumab trials in OCS dependent asthma: A: severe allergic asthma, 20–32 weeks treatment; and B: severe allergic asthma, 48–52 weeks treatment.

Apart from lung function and SAEs, we found no significant differences for the predefined critical or important clinical outcomes in the comparisons between dupilumab and mepolizumab. We found an absolute mean difference in FEV₁ of +100 mL (95% CI 13–188) at 24 weeks and +189 mL (62–316) at 52 weeks in favour of dupilumab. While both were significant, neither were above the prespecified MCID of 200 mL and no differences were observed for OCS dependent asthma. We found a significant increase in the proportion of SAEs in OCS dependent severe eosinophilic asthma at 24 weeks of treatment with an absolute difference of 26.0% (1.5–257.1) and relative difference of 19.5% (2.1–184.6) in favour of mepolizumab, which was above the MCID of 5% difference, but not significant in the non-OCS dependent groups (table 1). The risk of bias in the included studies assessed by the Cochrane risk of bias tool revealed some concerns due to selection bias. The overall quality of evidence assessed by GRADE was considered low.

In the comparisons between dupilumab and omalizumab only lung function showed significant results with an absolute mean difference in FEV₁ of +96 mL (11–182) at 48–52 weeks of treatment, which was below the prespecified MCID (table 1). The Cochrane risk of bias tool revealed some risk of bias due to incomplete descriptions in the included studies. Furthermore, the general quality of evidence assessed by GRADE was considered very low, due to low comparability of the studies.

These indirect comparisons of dupilumab *versus* mepolizumab and omalizumab treatment for severe type 2 asthma revealed no differences of clinical importance, except for an increase in SAEs in favour of mepolizumab among OCS dependent asthmatics although with a very wide confidence interval. Unfortunately, no head-to-head studies of biologics for severe type 2 asthma have been published and therefore our results are based on indirect comparisons of studies with varying population characteristics, inconsistency, and imprecise outcome definitions. Thus, the quality of the generated evidence is estimated to be low, but still presents the best comparison to date. Furthermore, the risk of bias in the omalizumab studies was considered high due to unclear methods and poor presentation of risk of bias. However, in the mepolizumab studies the risk of bias was in general considered low and in the dupilumab studies there was also a low risk of bias although there were some concerns regarding selection bias. For now, there is no evidence supporting that one of the investigated biologics is superior to another in patients eligible for more than one biologic, although dupilumab seems to have a better effect on lung function but may result in more SAEs. Furthermore, it is unknown whether specific subtypes of type 2 asthma will benefit more from dupilumab, mepolizumab or omalizumab.

In conclusion, by using indirect comparisons we found no clinically significant differences in efficacy outcomes between dupilumab, mepolizumab and omalizumab in patients aged >12 years with severe type 2 asthma characterised by eosinophilia and/or perennial allergy. Randomised controlled head-to-head comparisons of biologics for severe type 2 asthma are needed to aid treatment decisions.

Katrine Prætorius¹, Daniel P. Henriksen², Johannes M. Schmid³, Pernille Printzlau⁴, Lars Pedersen⁵, Hanne Madsen⁶, Ehm A. Andersson⁷, Louise Klokke Madsen⁷ and Bo L. Chawes^{1,8}

¹Dept of Pediatric and Adolescent Medicine, Herlev and Gentofte Hospital, Copenhagen, Denmark.

²Dept of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.

³Dept of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark. ⁴The Capital Region Pharmacy, North Zealand Hospital, Hillerød, Denmark. ⁵Dept of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark. ⁶Dept of Respiratory Medicine, Odense University Hospital, Odense, Denmark. ⁷The Danish Medicines Council Secretariat, Copenhagen, Denmark.

⁸COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.

Corresponding author: Bo L. Chawes (chawes@copsac.com)

Provenance: Submitted article, peer reviewed.

Conflict of interest: None declared.

References

- 1 Robinson D, Humbert M, Buhl R, *et al.* Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. *Clin Exp Allergy* 2017; 47: 161–175.
- 2 Henriksen DP, Bodtger U, Sidenius K, *et al.* Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis. *Eur Clin Respir J* 2018; 5: 1536097.
- 3 Henriksen DP, Bodtger U, Sidenius K, *et al.* Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. *Allergy Asthma Clin Immunol* 2020; 16: 49.
- 4 Agache I, Song Y, Rocha C, *et al.* Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of EAACI guidelines – recommendations on the use of biologics in severe asthma. *Allergy* 2020; 75: 1058–1068.
- 5 Castro M, Corren J, Pavord ID, *et al.* Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *N Engl J Med* 2018; 378: 2486–2496.
- 6 Corren J, Castro M, Chanez P, *et al.* Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. *Ann Allergy Asthma Immunol* 2019; 122: 41–49.
- 7 Corren J, Castro M, O’Riordan T, *et al.* Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. *J Allergy Clin Immunol Pract* 2020; 8: 516–526.
- 8 Rabe KF, Nair P, Brusselle G, *et al.* Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med* 2018; 378: 2475–2485.
- 9 Wenzel S, Castro M, Corren J, *et al.* Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β_2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet* 2016; 388: 31–44.
- 10 Wenzel S, Castro M, Corren J, *et al.* Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long acting β_2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet* 2016; 388: 31–44.
- 11 Corren J, Castro M, Chanez P, *et al.* Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. *Ann Allergy Asthma Immunol* 2019; 122: 41–49.
- 12 Castro M, Corren J, Pavord ID, *et al.* Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *N Engl J Med* 2018; 378: 2486–2496.
- 13 Corren J, Castro M, O’Riordan T, *et al.* Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. *J Allergy Clin Immunol Pract* 2020; 8: 516–526.
- 14 Rabe KF, Nair P, Brusselle G, *et al.* Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med* 2018; 378: 2475–2485.
- 15 Pavord ID, Korn S, Howarth P, *et al.* Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet* 2012; 380: 651–659.
- 16 Ortega HG, Liu MC, Pavord ID, *et al.* Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med* 2014; 371: 1198–1207.
- 17 Chupp GL, Bradford ES, Albers FC, *et al.* Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. *Lancet Respir Med* 2017; 5: 390–400.
- 18 Bel EH, Wenzel SE, Thompson PJ, *et al.* Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med* 2014; 371: 1189–1197.
- 19 Busse W, Corren J, Lanier BQ, *et al.* Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. *J Allergy Clin Immunol* 2001; 108: 184–190.
- 20 Finn A, Gross G, van Bavel J, *et al.* Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. *J Allergy Clin Immunol* 2003; 111: 278–284.
- 21 Lanier BQ, Corren J, Lumry W, *et al.* Omalizumab is effective in the long-term control of severe allergic asthma. *Ann Allergy Asthma Immunol* 2003; 91: 154–159.
- 22 Solèr M, Matz J, Townley R, *et al.* The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. *Eur Respir J* 2001; 18: 254–261.
- 23 Buhl R, Hanf G, Solèr M, *et al.* The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. *Eur Respir J* 2002; 20: 1088–1094.
- 24 Buhl R, Solèr M, Matz J, Townley R, O’Brien J, Noga O, *et al.* Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. *Eur Respir J*. 2002;20: 73–78.
- 25 Holgate ST, Chuchalin AG, Hébert J, *et al.* Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. *Clin Exp Allergy* 2004; 34: 632–638.

- 26 Vignola AM, Humbert M, Bousquet J, *et al.* Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. *Allergy* 2004; 59: 709–717.
- 27 Ayres JG, Higgins B, Chilvers ER, *et al.* Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. *Allergy* 2004; 59: 701–708.
- 28 Niven R, Chung KF, Panahloo Z, *et al.* Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. *Respir Med* 2008; 102: 1371–1378.
- 29 Humbert M, Beasley R, Ayres J, *et al.* Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. *Allergy* 2005; 60: 309–316.
- 30 Ohta K, Miyamoto T, Amagasaki T, *et al.* Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. *Respirology* 2009; 14: 1156–1165.
- 31 Chanez P, Contin-Bordes C, Garcia G, *et al.* Omalizumab-induced decrease of Fc ϵ RI expression in patients with severe allergic asthma. *Respir Med* 2010; 104: 1608–1617.
- 32 Bousquet J, Siergiejko Z, Swiebocka E, *et al.* Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. *Allergy* 2011; 66: 671–678.
- 33 Siergiejko Z, Swiebocka E, Smith N, *et al.* Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. *Curr Med Res Opin* 2011; 27: 2223–2228.
- 34 Hanania NA, Alpan O, Hamilos DL, *et al.* Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. *Ann Intern Med* 2011; 154: 573–582.
- 35 Bardelas J, Figliomeni M, Kianifard F, *et al.* A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. *J Asthma* 2012; 49: 144–152.
- 36 Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. *Respiration* 2012; 83: 520–528.
- 37 Rubin AS, Souza-Machado A, Andrade-Lima M, *et al.* Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). *J Asthma* 2012; 49: 288–293.
- 38 Busse W, Spector S, Rosén K, *et al.* High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. *J Allergy Clin Immunol* 2013; 132: 485–486.
- 39 Li J, Kang J, Wang C, *et al.* Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a randomized phase iii study. *Allergy Asthma Immunol Res* 2016; 8: 319–328.
- 40 Mukherjee M, Kjarsgaard M, Radford K, *et al.* Omalizumab in patients with severe asthma and persistent sputum eosinophilia. *Allergy Asthma Clin Immunol* 2019; 15: 21.